SynthesisMedicina (Kaunas, Lithuania)2022
Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
Synthesis in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Prognostic value of neutrophil to lymphocyte ratio in patients with esophagus cancer receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis.Pathology oncology research : POR · 2024Pooled it
- Cancer risk and mortality assessment in the overweight population: evaluation of single and integrated models based on inflammatory markers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Prognostic Value of the Lung Immune Prognostic Index and an ECOG-Albumin-LIPI Nomogram in Metastatic NSCLC Patients Treated with Second- or Third-Line Nivolumab.Journal of clinical medicine · 2026Article
- Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy.Biomedicines · 2026Article
- Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.Journal of clinical medicine · 2026Article
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.Scientific reports · 2026Article
- Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients.Journal of personalized medicine · 2026Article
- Prognostication of non-small cell lung cancer with concurrent chemoradiation treatment using neutrophil-to-lymphocyte ratio.Radiation oncology journal · 2026Article
- Prognostic Value of Systemic Inflammation Markers (NLR and Haemoglobin) in Non-Small Cell Lung Cancer: Survival Analysis from a Real-World Single-Centre Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers.Current oncology (Toronto, Ont.) · 2026Article
- Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.Translational lung cancer research · 2026Article
- Prediction of tumor-infiltrating lymphocytes through habitat radiomics and exploration of response mechanisms in neoadjuvant immunochemotherapy-treated lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2026Article
- Article
- Tumor-associated neutrophils in lung adenocarcinoma: from mechanisms to therapeutic targeting.Frontiers in immunology · 2026Review
- Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study.BMC cancer · 2025Observational
- Peripheral blood cells predict the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma.BMC cancer · 2025Article
- The Prognostic Role of Different Blood Cell Count-to-Lymphocyte Ratios in Patients with Lung Cancer at Diagnosis.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Advanced non-small-cell lung cancer (NSCLC) has led to a high number of mortalities. Immunotherapy, as a first-line treatment in advanced NSCLC, currently has no clarity regarding its prognostic markers to assess the treatment outcome. This systematic review aimed to evaluate neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in advanced NSCLC patients treated with immunotherapy. Materials and Methods: This systematic review was conducted using the PRISMA guidelines, starting from screening for relevant studies from several databases. Each included cohort study was further assessed by using the Newcastle−Ottawa Quality Assessment Scale, and the available data were extracted for qualitative and quantitative synthesis in pooled and subgroup analysis. Results: A total of 1719 patients were included in this meta-analysis. Hazard ratio (HR) outcomes for progression-free survival (PFS) and overall survival (OS) for NLR and PLR showed significant results, supporting NLR and PLR as prognostic markers (NLR: HR PFS 2.21 [95% CI: 1.50−3.24; p < 0.0001] and HR OS 2.68 [95% CI: 2.24−3.6; p < 0.0001]; PLR: HR PFS 1.57 [95% CI: 1.33−1.84; p < 0.00001] and HR OS 2.14 [95% CI: 1.72−2.67; p < 0.00001]). Subgroup analysis with a cut-off value of 5 for NLR and 200 for PLR also demonstrated notable outcomes. Higher NLR and PLR levels are associated with poor prognostic. Conclusions: There is considerable evidence regarding both markers as prognostic markers in NSCLC patients treated with immunotherapy. However, further studies with more homogeneous baseline characteristics are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.